OGN 241220 17.50C (OGN241220C17500) Stock Options, News & Quotes

0.03
-0.01-25.00%

15min DelayClose Dec 13 15:04 ET

0.04High0.03Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Oct 28 08:26

NEWS

$Organon & Co (OGN.US)$
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA(R) (tapinarof) Cream, 1%
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA(R) (tapinarof) Cream, 1%
The acquisition expands Organon's dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.
BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global health...

Meltyy

Oct 11 01:22

🚨 M&A Update! 🚨

Keep an eye on these recently announced & closed M&As: 👀
🟢 Recently Announced:
⇒ $Organon & Co (OGN.US)$ to acquire Dermavant
⇒ $Rafael Holdings (RFL.US)$ to acquire Cyclo Tx
⇒Crown Lab to acquire $Revance Therapeutics (RVNC.US)$
⇒ $Recursion Pharmaceuticals (RXRX.US)$ merger with Exscientia
🔴 Recently Closed:
⇒ $Johnson & Johnson (JNJ.US)$ acquired V-Wave
⇒ Pharmacosmos acquired $GTHX
What companies will be next? 🤔

whqqq

Jul 29 21:17

Cramer’s Lightning Round: Do not sell Constellation Energy

$Bank of America (BAC.US)$ : ”...You buy some right here, you buy some maybe if it breaks 40. I think this company is selling very inexpensively, and it’s a good one.”
$Illumina (ILMN.US)$ : “No. No Illumina. I like Danaher.”
$Constellation Energy (CEG.US)$ : “This is a solar play that is a very good company. It’s up a huge amount versus a lot of other stocks...I think you buy some, please hold on to it, do not sell it.”
$Meta Platforms (META.US)$ : “I thin...

https://www.youtube.com/watch?v=X4PV1Nqu1QU

From YouTube

Moomoo AI

Apr 6 07:51

Organon's low P/E ratio is due to its predicted growth being less than the broader market. Shareholders accept this as they anticipate future earnings won't bring any pleasant surprises. The share price is unlikely to rise significantly soon under these conditions.

Organon & Co.'s (NYSE:OGN) Earnings Are Not Doing Enough For Some Investors

Moomoo AI

Feb 18 17:32

Analysts show increased negativity towards the business following recent results, reflected in a minor decrease in next year's EPS estimates. Despite predicted earnings decline, Organon's valuation is not expected to be significantly affected, but growth is anticipated to lag behind the industry.

Organon & Co. Just Beat EPS By 70%: Here's What Analysts Think Will Happen Next